Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin

NCT02604641 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-10-08

No results posted yet for this study

Summary

Objective of the study is to determine the influence of dietary supplementation with coenzyme Q10 (CoQ10) on skin conditions. 33 healthy female subjects will be randomly assigned to a placebo group, a low-dose (LD) group receiving 50 mg CoQ10/day and a high-dose group (HD) receiving 150 mg CoQ10/day (11 subjects per group). A water-soluble form of CoQ10 with improved bioavailability (Quvital syrup with Q10vital®, Valens Int. d.o.o., Slovenia) will be used. Various skin parameters will be evaluated before the supplementation (the baseline), after 6 and after 12 weeks of supplementation. To evaluate the photoprotective potential of CoQ10 the minimal erythema dose (MED) will be determined before (the baseline) and after 12 weeks of the supplementation.

Conditions

  • Wrinkles
  • Ageing
  • Photoprotection

Interventions

DIETARY_SUPPLEMENT

Placebo group

Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.

DIETARY_SUPPLEMENT

Quvital LD group

Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.

DIETARY_SUPPLEMENT

Quvital HD group

Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.

Sponsors & Collaborators

  • Valens Int. d.o.o., Slovenija

    collaborator INDUSTRY
  • Institute of Nutrition, Slovenia (Nutris)

    collaborator OTHER
  • VIST - Faculty of Applied Sciences

    lead OTHER

Principal Investigators

  • Janko Zmitek, PhD · VIST - Faculty of Applied Sciences

  • Katja Zmitek, PhD · VIST - Faculty of Applied Sciences

  • Liljana Mervic, PhD · UL MF

  • Tina Tina Pogačnik, BSc · VIST - Faculty of Applied Sciences

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-05-31
Completion
2015-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02604641 on ClinicalTrials.gov